193 related articles for article (PubMed ID: 9306332)
21. 5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review.
Moss JG; Parry CM; Holt RCL; McWilliam SJ
Eur J Med Res; 2022 Apr; 27(1):61. PubMed ID: 35488310
[TBL] [Abstract][Full Text] [Related]
22. Mesalamine-induced pneumonitis during therapy for chronic inflammatory bowel disease: a pediatric case report.
Kohli R; Melin-Aldana H; Sentongo TA
J Pediatr Gastroenterol Nutr; 2005 Oct; 41(4):479-82. PubMed ID: 16205520
[No Abstract] [Full Text] [Related]
23. [Nephrogenic diabetes insipidus secondary to chronic interstitial nephritis associated with mesalazine therapy].
García-Martín F; Sánchez Heras M; Sánchez Martínez L; Rodríguez-Zapata M
Rev Clin Esp; 2002 Apr; 202(4):245-6. PubMed ID: 12003743
[No Abstract] [Full Text] [Related]
24. Which are the 5-ASA compound side effects and how is it possible to avoid them?
Moum B
Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S212-3. PubMed ID: 18816767
[No Abstract] [Full Text] [Related]
25. Acute tubulointerstitial nephritis due to 5-aminosalicylic acid in a patient with ulcerative colitis and chronic renal failure.
Tekin F; Ozütemiz O; Ilter T
Turk J Gastroenterol; 2006 Jun; 17(2):153-4. PubMed ID: 16830305
[No Abstract] [Full Text] [Related]
26. Mesalazine-induced interstitial nephritis.
Skalova S; Dedek P; Pozler O; Podhola M
Ren Fail; 2009; 31(2):159-61. PubMed ID: 19212915
[TBL] [Abstract][Full Text] [Related]
27. Methaemoglobinaemia and renal failure following mesalazine for treatment of inflammatory bowel disease.
Druez A; Rahier JF; Hébuterne X
J Crohns Colitis; 2014 Aug; 8(8):900-1. PubMed ID: 24486176
[No Abstract] [Full Text] [Related]
28. [Chronic interstitial nephritis and mesalazine: 3 new cases?].
Brouillard M; Gheerbrant JD; Gheysens Y; Fleury D; Devred M; Hazzan M; Colombel JF
Gastroenterol Clin Biol; 1998; 22(8-9):724-6. PubMed ID: 9823562
[TBL] [Abstract][Full Text] [Related]
29. Chronic tubulointerstitial nephritis induced by 5-aminosalicylate in an ulcerative colitis patient: a rare but serious adverse event.
Magalhães-Costa P; Matos L; Chagas C
BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25935912
[TBL] [Abstract][Full Text] [Related]
30. Hypereosinophilia due to mesalazine treatment.
Usta Y; Ozen H; Gurakan F; Uslu N; Saltik-Temizel IN; Demir H; Yuce A
J Clin Gastroenterol; 2009 Apr; 43(4):382. PubMed ID: 19309777
[No Abstract] [Full Text] [Related]
31. Mesalamine: safe at first look.
Saubermann LJ; Wolf JL
Inflamm Bowel Dis; 1999 May; 5(2):148-9. PubMed ID: 10338388
[No Abstract] [Full Text] [Related]
32. Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine.
Margetts PJ; Churchill DN; Alexopoulou I
J Clin Gastroenterol; 2001 Feb; 32(2):176-8. PubMed ID: 11205659
[TBL] [Abstract][Full Text] [Related]
33. [Tubulo-interstitial nephritis in inflammatory bowel disease: extra-intestinal manifestation or drug toxicity?].
Heidt J; Ooms EC; van der Werf SD; Groeneveld JH
Ned Tijdschr Geneeskd; 2010; 154():A1647. PubMed ID: 20699041
[TBL] [Abstract][Full Text] [Related]
34. 5-Aminosalicylic acid.
Iida T; Onodera K; Nakase H
Nihon Rinsho; 2017 Mar; 75(3):392-397. PubMed ID: 30566780
[TBL] [Abstract][Full Text] [Related]
35. Late onset interstitial nephritis associated with mesalazine treatment.
Popoola J; Muller AF; Pollock L; O'Donnell P; Carmichael P; Stevens P
BMJ; 1998 Sep; 317(7161):795-7. PubMed ID: 9740571
[No Abstract] [Full Text] [Related]
36. Safety of high doses of mesalazine during pregnancy.
Marteau P; Seksik P; Couve S; Jian R
Am J Gastroenterol; 2005 Aug; 100(8):1897-8. PubMed ID: 16086733
[No Abstract] [Full Text] [Related]
37. Massive pericardial effusion in a child following the administration of mesalamine.
Kaiser GC; Milov DE; Erhart NA; Bailey DJ
J Pediatr Gastroenterol Nutr; 1997 Oct; 25(4):435-8. PubMed ID: 9327378
[No Abstract] [Full Text] [Related]
38. [Interstitial nephritis after treatment with mesalazine in the patient with ulcerative colitis].
Maeda S; Nomura S; Tahara M; Haneda M; Kikkawa R
Nihon Naika Gakkai Zasshi; 2001 May; 90(5):872-3. PubMed ID: 11460356
[No Abstract] [Full Text] [Related]
39. [Renal involvement in patients with chronic inflammatory intestinal disease treated with mesalazine. How to prevent its nephrotoxicity?].
Bonet J; Vaquero M; Bayés B; Romero R
Med Clin (Barc); 1999 Jul; 113(5):199. PubMed ID: 10480148
[No Abstract] [Full Text] [Related]
40. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
Klotz U
Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
